IP Library Granted Patent US 12,544,576
Granted Patent B2
US 12,544,576 · App. 18/151,004 · Granted Feb 10, 2026

Treatment of inflammatory disorders

Inventors: Philippe Blancou (Nice, FR); Nicolas Glaichenhaus (Nice, FR); Arun Sridhar (Stevenage, GB)
Assignee: Galvani Bioelectronics Limited
A61N1/36139A61N1/36157A61N1/36171A61N1/37211
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,544,576
App. No.
18/151,004
Granted
Feb 10, 2026
Kind
B2
Abstract

Devices and methods for the stimulation of neural signalling of an apical splenic nerve, the device having a transducer for placement on or around the apical splenic nerve, and a signal generator to generate a signal that stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response. The transducer has at least one electrode, and the signal generator is a voltage or current source. The stimulation electrical signal has a frequency of between 1 Hz and 50 Hz.

Claims (22)

1 . A device or system for stimulating neural activity of an apical splenic nerve, the device or system comprising:

at least one transducer configured for placement on or around the apical splenic nerve, wherein the apical splenic nerve is a non-arteriolar associated nerve located at an apex of a spleen, wherein the apical splenic nerve enters a superior pole of the spleen, and

a signal generator configured for generating at least one signal to be applied to the apical splenic nerve via the at least one transducer, wherein the at least one signal stimulates or inhibits the neural activity of the apical splenic nerve to produce a physiological response in a subject, wherein the physiological response is one or more of the group consisting of: a reduction in pro-inflammatory cytokines, an increase in anti-inflammatory cytokines, an increase in catecholamines, changes in immune cell population or immune cell surface co-stimulatory molecules, a reduction in factors involved in an inflammation cascade or a reduction in immune response mediators; wherein the at least one transducer is at least one electrode; wherein the signal generator is a voltage or current source configured to generate the at least one electrical signal to be applied to the apical splenic nerve via the at least one electrode, and wherein the at least one electrical signal has a frequency of between 1 and 50 Hz.

2 . The device or system of claim 1 , wherein the east one electrical signal is an AC signal.

3 . The device or system of claim 1 , wherein the at least one electrical signal comprises one or more pulse trains, each pulse train comprising a plurality of square or sawtooth pulses, wherein the plurality of pulses are delivered at a frequency in a range of 1 to 50 Hz.

4 . The device or system of claim 3 , wherein the plurality of square or sawtooth pulses are delivered at a frequency of 1 Hz, 5 Hz or 10 Hz.

5 . The device or system of claim 3 , wherein the square or sawtooth pulses have a duration of between 10 μs and 5 ms.

6 . The device or system of claim 3 , wherein the square or sawtooth pulses are bipolar pulses.

7 . The device or system of claim 3 , wherein the square or sawtooth pulses have a constant current of between 200 HA and 5 mA.

8 . The device or system of claim 3 , wherein the at least one electrical signal is delivered for between 30 seconds and 5 minutes.

9 . The device or system of claim 1 , wherein the signal generator is configured to apply the at least one electric signal periodically.

10 . The device or system of claim 1 , wherein the device modulates neural activity of the apical splenic nerve.

11 . The device or system of claim 3 , wherein the square or sawtooth pulses have a duration of between 20 μs and 4 ms.

12 . The device or system of claim 3 , wherein the square or sawtooth pulses have a duration of between 50 μs and 2 ms.

13 . The device or system of claim 3 , wherein the square or sawtooth pulses have a duration of between 100 μs and 1 ms.

14 . The device or system of claim 3 , wherein the square or sawtooth pulses have a duration of between 200 μs and 500 μs.

15 . The device or system of claim 3 , wherein the at least one electrical signal comprises one or more pulse trains, each comprising a plurality of square or sawtooth pulses, wherein the plurality of pulses are delivered at a frequency between 1 and 30 Hz.

16 . The device or system of claim 3 , wherein the square or sawtooth pulses have a constant current of 600 μA.

17 . The device or system of claim 8 , wherein the at least one electrical signal is delivered for 2 minutes.

18 . A method of reversibly stimulating neural activity in an apical splenic nerve, comprising: (i) implanting a device configured for stimulating the neural activity of an apical splenic nerve into the subject; (ii) positioning a transducer in signalling contact with an apical splenic nerve, wherein the apical splenic nerve is a non-arteriolar associated nerve located at an apex of the spleen, wherein the apical splenic nerve enters a superior pole of the spleen; and (iii) activating the device.

19 . The method of claim 18 , wherein the patient suffers from an inflammatory disorder.

20 . A method of treating in a subject who suffers from, or is at risk of, inflammatory disorder, comprising: (i) implanting a device configured for stimulating neural activity of an apical splenic nerve into the subject; (ii) positioning a transducer in signaling contact with an apical splenic nerve, wherein the apical splenic nerve is a non-arteriolar associated nerve located at an apex of the spleen, wherein the apical splenic nerve enters a superior pole of the spleen; and (iii) activating the device.

Assignments (7)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GALVANI BIOELECTRONICS LIMITED
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 070854/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: SRIDHAR, ARUN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 062312/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 062312/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: BLANCOU, PHILIPPE; GLAICHENHAUS, NICOLAS
To: UNIVERSITÉ DE NICE SOPHIA-ANTIPOLIS; CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 062312/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: UNIVERSITÉ NICE SOPHIA-ANTIPOLIS
To: UNIVERSITÉ CÔTE D'AZUR
Reel/Frame 062312/0384 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: SRIDHAR, ARUN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 062324/0485 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 062324/0509 →
Priority Claims (1)
GB 1618838 · Nov 8, 2016 · national
Continuity (2)
Continuation 16347940
Related Publication 20230142770A1 · May 11, 2023
References Cited (29)
US 9415220B1 · Spinelli et al. · 2016 [cited by applicant]
US 20050075701A1 · Shafer · 2005 [cited by applicant]
US 20050075702A1 · Shafer · 2005 [cited by examiner]
US 20060287678A1 · Shafer · 2006 [cited by applicant]
US 20110152748A1 · Della Rocca · 2011 [cited by examiner]
US 20110160798A1 · Ackermann, Jr. et al. · 2011 [cited by applicant]
US 20140288551A1 · Bharmi · 2014 [cited by examiner]
US 20150174397A1 · Bhadra et al. · 2015 [cited by applicant]
US 20170120046A1 · Schwab et al. · 2017 [cited by applicant]
US 20190321640A1 · Carmena · 2019 [cited by examiner]
US 20200046992A1 · Tracey · 2020 [cited by examiner]
US 20220409887A1 · Gupta · 2022 [cited by examiner]
US 20240285944A1 · Covalin · 2024 [cited by examiner]
US 20240307688A1 · Levine · 2024 [cited by examiner]
WO 2013086175A1 · 2013 [cited by applicant]
R. Medzhitov, Origin and physiological roles of inflammation., Nature 454, 428-435 (Jul. 24, 2008). [cited by applicant]
J. M. Huston et al., Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis., J Exp Med (2006) 203 (7): 1623-1628. [cited by applicant]
Nance et al., Autonomic innervation and regulation of the immune system (1987-2007)., Brain, Behavior, and Immunity, vol. 21, Issue 6, Aug. 2007, pp. 736-745. [cited by applicant]
Dale et al., The presence of histamine and acetylcholine in the spleen of the ox and the horse., J Physiol vol. 68, Issue 2, Oct. 23, 1929, pp. 97-123. [cited by applicant]
Cailotto et al., Neuroanatomical evidence demonstrating the existence of the vagal anti?inflammatory reflex in the intestine., Neurogastroenteroly & Motility, vol. 24, Issue 2, Feb. 2012, pp. 191-e93. [cited by applicant]
Rosas-Ballina et al., The Neurology of the Immune System: Neural Reflexes Regulate Immunity., vol. 64, Issue 1, Oct. 15, 2009, pp. 28-32. [cited by applicant]
Vida et al., α7-Cholinergic Receptor Mediates Vagal Induction of Splenic Norepinephrine., J Immunol Apr. 1, 2011, 186 (7) 4340-4346. [cited by applicant]
Bratton et al., Neural regulation of inflammation: No. neural connection from the vagus to splenic sympathetic neurons., Exp Physiol 97, 1180, Nov. 2012. [cited by applicant]
Martelli et al., Reflex control of inflammation by sympathetic nerves, not the vagus., J Physiol 592(7), 1677. Apr. 1, 2014. [cited by applicant]
Martelli, et al., , Reflex control of inflammation by the splanchnic anti-inflammatory pathway is sustained and independent of anesthesia., Am J Physiol Regul Integr Comp Physiol 307, R1085. Nov. 2014. [cited by applicant]
Martelli et al., The cholinergic anti-inflammatory pathway: A critical review., Autonomic Neuroscience, vol. 182, May 2014, pp. 65-69. [cited by applicant]
Koopman FA et al., Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis., Proc Natl Acad Sci USA, Jul. 19, 2016 113 (29) 8284-8289; first published Jul. 5, 2016. [cited by applicant]
Buijs R M, et al., Spleen Vagal Denervation Inhibits the Production of Antibodies to Circulating Antigens., PLoS One. Sep. 2008. 5; 3(9):e3152. [cited by applicant]
Guyot, M., Simon, T., Panzolini, C., Ceppo, F., Daoudlarian, D., Murris, E., . . . & Blancou, P. (2019). Apical splenic nerve electrical stimulation discloses an anti-inflammatory pathway relying on adrenergic and nicot… [cited by applicant]